John Oyler - BeiGene Chairman of the Board, CEO, Founder
| BGNE Stock | USD 162.25 0.24 0.15% |
Chairman
Mr. John Victor Oyler is Executive Chairman of the Board, Chief Executive Officer of the Company. He has served as a member of our Board since October 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corporationration, a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1998 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was bought by The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as CoChief Executive Officer of Genta Incorporated, an oncologyfocused biopharmaceutical company listed on the Nasdaq under ticker symbol GNTA. Mr. Oyler began his career as a management consultant at McKinsey Company since 2010.
| Age | 56 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Address | 94 Solaris Avenue, Grand Cayman, Cayman Islands, KY1-1108 |
| Phone | 345 949 4123 |
| Web | https://www.beigene.com |
Latest Insider Transactions
Oyler received his B.S. from the Massachusetts Institute of Technology in June, 1990 and an MBA from Stanford University in January, 1996.John Oyler Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Oyler against BeiGene stock is an integral part of due diligence when investing in BeiGene. John Oyler insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Oyler over three weeks ago Disposition of tradable shares by John Oyler of BeiGene at 150.85 subject to Rule 16b-3 | ||
John Oyler over three weeks ago Disposition of 7924 shares by John Oyler of BeiGene at 154.2084 subject to Rule 16b-3 | ||
John Oyler over a month ago Disposition of 200 shares by John Oyler of BeiGene at 169.05 subject to Rule 16b-3 |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.124) % which means that it has lost $0.124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2226) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of May 4, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 215.8 M, whereas Non Currrent Assets Other are projected to grow to (17.8 M).Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Pierre Lapalme | Biomarin Pharmaceutical | 73 | |
| JeanJacques Bienaime | Biomarin Pharmaceutical | 64 | |
| Stanley Crooke | Ionis Pharmaceuticals | 79 | |
| Douglas Given | Arrowhead Pharmaceuticals | 62 | |
| Michael Jensen | Ascendis Pharma AS | 41 | |
| Julian Baker | Incyte | 51 | |
| Edward Frykman | Arrowhead Pharmaceuticals | 80 | |
| Daniel Lynch | Blueprint Medicines Corp | 60 | |
| Gerald Chan | Apellis Pharmaceuticals | 66 | |
| Herve Hoppenot | Incyte | 64 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, Chairman CoFounder | ||
| Howard Liang, CFO and Chief Strategy Officer | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Jason Yang, Senior Vice President Head of Clinical Development | ||
| Wang Lai, Global RD | ||
| Thomas Malley, Non-Executive Independent Director | ||
| Eric Hedrick, Interim Chief Medical Officer, Immuno-Oncology | ||
| Qingqing Yi, Director | ||
| Titus Ball, VP Officer | ||
| Julia Wang, CFO Officer | ||
| Hing Chau, Company Secretary | ||
| Daniel Maller, VP Accounting | ||
| Timothy Chen, Director | ||
| Wendy Yan, Senior Vice President Head of Regulatory Affairs | ||
| Ke Tang, Director | ||
| Xiaobin Wu, President COO | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Ranjeev Krishana, Director | ||
| Chan Lee, General VP | ||
| Donald Glazer, Director | ||
| Kevin Mannix, VP Relations | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Michael Goller, Director | ||
| JingShyh Su, Independent Director | ||
| Diana Francis, VP Compliance | ||
| Yan Qi, Senior China | ||
| Jane Huang, Chief Medical Officer, Hematology |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 218.01 B | ||||
| Shares Outstanding | 104.52 M | ||||
| Shares Owned By Insiders | 19.82 % | ||||
| Shares Owned By Institutions | 47.89 % | ||||
| Number Of Shares Shorted | 1.84 M | ||||
| Price To Earning | (16.19) X |
Pair Trading with BeiGene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BeiGene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BeiGene will appreciate offsetting losses from the drop in the long position's value.Moving together with BeiGene Stock
| 0.66 | VTYX | Ventyx Biosciences Financial Report 9th of May 2024 | PairCorr |
Moving against BeiGene Stock
| 0.6 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.42 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to BeiGene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BeiGene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BeiGene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BeiGene to buy it.
The correlation of BeiGene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BeiGene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BeiGene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BeiGene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is BeiGene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.45) | Revenue Per Share 23.554 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.22) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.